Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-6: Ivermectin in Outpatient COVID-19
NCT05736861Phase 3Completed
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ivermectin with Placebo (2 arms). Primary endpoint: Time to Sustained Recovery in Days at 28 days. Started Jun 2021; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05736861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736861.